Literature DB >> 32089543

PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.

Masaharu Kawashima1,2, Joaquim Carreras3, Hiroshi Higuchi1,4, Ryutaro Kotaki1, Takahiro Hoshina1,5, Kazuki Okuyama1, Naoto Suzuki1,6,7, Masatoshi Kakizaki1, Yuji Miyatake1, Kiyoshi Ando8, Masafumi Nakayama9, Shinjiro Umezu10, Ryouichi Horie11, Yuriko Higuchi12, Koko Katagiri6, Susumu Goyama5, Toshio Kitamura5, Kenji Chamoto13, Shingo Yano2, Naoya Nakamura3, Ai Kotani14,15,16.   

Abstract

In classical Hodgkin lymphoma (cHL)-characterized by the presence of Hodgkin and Reed-Sternberg (HRS) cells-tumor-associated macrophages (TAMs) play a pivotal role in tumor formation. However, the significance of direct contact between HRS cells and TAMs has not been elucidated. HRS cells and TAMs are known to express PD-L1, which leads to PD-1+ CD4+ T cell exhaustion in cHL. Here, we found that PD-L1/L2 expression was elevated in monocytes co-cultured with HRS cells within 1 h, but not in monocytes cultured with supernatants of HRS cells. Immunofluorescence analysis of PD-L1/L2 revealed that their upregulation resulted in membrane transfer called "trogocytosis" from HRS cells to monocytes. PD-L1/L2 upregulation was not observed in monocytes co-cultured with PD-L1/L2-deficient HRS cells, validating the hypothesis that there is a direct transfer of PD-L1/L2 from HRS cells to monocytes. In the patients, both ligands (PD-L1/L2) were upregulated in TAMs in contact with HRS cells, but not in TAMs distant from HRS cells, suggesting that trogocytosis occurs in cHL patients. Taken together, trogocytosis may be one of the mechanisms that induces rapid upregulation of PD-L1/L2 in monocytes to evade antitumor immunity through the suppression of T cells as mediated by MHC antigen presentation.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32089543     DOI: 10.1038/s41375-020-0737-9

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  51 in total

1.  Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.

Authors:  Luis F Porrata; Kay Ristow; Joseph P Colgan; Thomas M Habermann; Thomas E Witzig; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Grzegorz S Nowakowski; Carrie Thompson; Svetomir N Markovic
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

Review 2.  The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

Authors:  Donatella Aldinucci; Annunziata Gloghini; Antonio Pinto; Rosaria De Filippi; Antonino Carbone
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

3.  Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients.

Authors:  Tamar Tadmor; Alessia Bari; Luigi Marcheselli; Stefano Sacchi; Ariel Aviv; Luca Baldini; Paolo G Gobbi; Samantha Pozzi; Paola Ferri; Maria Christina Cox; Nicola Cascavilla; Emilio Iannitto; Massimo Federico; Aaron Polliack
Journal:  Mayo Clin Proc       Date:  2015-06       Impact factor: 7.616

Review 4.  Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.

Authors:  Christian Steidl; Joseph M Connors; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 5.  Hodgkin lymphoma.

Authors:  Ralf Küppers; Andreas Engert; Martin-Leo Hansmann
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 6.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

7.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Authors:  Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

8.  Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes.

Authors:  Yue Ma; Lydia Visser; Han Roelofsen; Marcel de Vries; Arjan Diepstra; Gustaaf van Imhoff; Tineke van der Wal; Marjan Luinge; Gloria Alvarez-Llamas; Hans Vos; Sibrand Poppema; Roel Vonk; Anke van den Berg
Journal:  Blood       Date:  2007-12-10       Impact factor: 22.113

9.  Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.

Authors:  King L Tan; David W Scott; Fangxin Hong; Brad S Kahl; Richard I Fisher; Nancy L Bartlett; Ranjana H Advani; Rena Buckstein; Lisa M Rimsza; Joseph M Connors; Christian Steidl; Leo I Gordon; Sandra J Horning; Randy D Gascoyne
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

10.  Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma.

Authors:  Baoping Guo; Hong Cen; Xiaohong Tan; Qing Ke
Journal:  BMC Med       Date:  2016-10-17       Impact factor: 8.775

View more
  12 in total

Review 1.  An Update on the Pathology and Molecular Features of Hodgkin Lymphoma.

Authors:  Akira Satou; Taishi Takahara; Shigeo Nakamura
Journal:  Cancers (Basel)       Date:  2022-05-26       Impact factor: 6.575

Review 2.  Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma.

Authors:  Naike Casagrande; Cinzia Borghese; Donatella Aldinucci
Journal:  Cancers (Basel)       Date:  2022-05-14       Impact factor: 6.575

Review 3.  Trogocytosis between Non-Immune Cells for Cell Clearance, and among Immune-Related Cells for Modulating Immune Responses and Autoimmunity.

Authors:  Ko-Jen Li; Cheng-Han Wu; Cheng-Hsun Lu; Chieh-Yu Shen; Yu-Min Kuo; Chang-Youh Tsai; Song-Chou Hsieh; Chia-Li Yu
Journal:  Int J Mol Sci       Date:  2021-02-24       Impact factor: 5.923

Review 4.  CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.

Authors:  Alba Rodriguez-Garcia; Asis Palazon; Estela Noguera-Ortega; Daniel J Powell; Sonia Guedan
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

Review 5.  Molecular biology of Hodgkin lymphoma.

Authors:  Marc A Weniger; Ralf Küppers
Journal:  Leukemia       Date:  2021-03-08       Impact factor: 11.528

6.  Current progress of the tumor microenvironment in lymphoid malignancies.

Authors:  Kennosuke Karube
Journal:  J Clin Exp Hematop       Date:  2021

Review 7.  Gnawing Between Cells and Cells in the Immune System: Friend or Foe? A Review of Trogocytosis.

Authors:  Siyu Zhao; Lichao Zhang; Suoyu Xiang; Yunyi Hu; Zhongdao Wu; Jia Shen
Journal:  Front Immunol       Date:  2022-02-03       Impact factor: 7.561

8.  When killers become thieves: Trogocytosed PD-1 inhibits NK cells in cancer.

Authors:  Mohamed S Hasim; Marie Marotel; Jonathan J Hodgins; Elisabetta Vulpis; Olivia J Makinson; Sara Asif; Han-Yun Shih; Amit K Scheer; Olivia MacMillan; Felipe G Alonso; Kelly P Burke; David P Cook; Rui Li; Maria Teresa Petrucci; Angela Santoni; Padraic G Fallon; Arlene H Sharpe; Giuseppe Sciumè; André Veillette; Alessandra Zingoni; Douglas A Gray; Arleigh McCurdy; Michele Ardolino
Journal:  Sci Adv       Date:  2022-04-13       Impact factor: 14.957

Review 9.  The role of trogocytosis in immune surveillance of Hodgkin lymphoma.

Authors:  Qun Zeng; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2020-06-17       Impact factor: 8.110

Review 10.  Significance of trogocytosis and exosome-mediated transport in establishing and maintaining the tumor microenvironment in lymphoid malignancies.

Authors:  Masaharu Kawashima; Hiroshi Higuchi; Ai Kotani
Journal:  J Clin Exp Hematop       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.